119 related articles for article (PubMed ID: 26797420)
1. Long-term efficacy and downstream mechanism of anti-annexinA2 monoclonal antibody (anti-ANX A2 mAb) in a pre-clinical model of aggressive human breast cancer.
Sharma MC; Tuszynski GP; Blackman MR; Sharma M
Cancer Lett; 2016 Apr; 373(1):27-35. PubMed ID: 26797420
[TBL] [Abstract][Full Text] [Related]
2. Antibody-directed neutralization of annexin II (ANX II) inhibits neoangiogenesis and human breast tumor growth in a xenograft model.
Sharma M; Blackman MR; Sharma MC
Exp Mol Pathol; 2012 Feb; 92(1):175-84. PubMed ID: 22044461
[TBL] [Abstract][Full Text] [Related]
3. Annexin A2 (ANX A2): An emerging biomarker and potential therapeutic target for aggressive cancers.
Sharma MC
Int J Cancer; 2019 May; 144(9):2074-2081. PubMed ID: 30125343
[TBL] [Abstract][Full Text] [Related]
4. Important role of annexin A2 (ANXA2) in new blood vessel development in vivo and human triple negative breast cancer (TNBC) growth.
Sharma MC; Jain D
Exp Mol Pathol; 2020 Oct; 116():104523. PubMed ID: 32866522
[TBL] [Abstract][Full Text] [Related]
5. Exosomal Annexin II Promotes Angiogenesis and Breast Cancer Metastasis.
Maji S; Chaudhary P; Akopova I; Nguyen PM; Hare RJ; Gryczynski I; Vishwanatha JK
Mol Cancer Res; 2017 Jan; 15(1):93-105. PubMed ID: 27760843
[TBL] [Abstract][Full Text] [Related]
6. The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target.
Sharma MC; Sharma M
Curr Pharm Des; 2007; 13(35):3568-75. PubMed ID: 18220793
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation.
Sharma M; Ownbey RT; Sharma MC
Exp Mol Pathol; 2010 Apr; 88(2):278-86. PubMed ID: 20079732
[TBL] [Abstract][Full Text] [Related]
8. Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: possible biochemical mechanism of angiostatin's action.
Sharma MR; Rothman V; Tuszynski GP; Sharma MC
Exp Mol Pathol; 2006 Oct; 81(2):136-45. PubMed ID: 16643891
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression.
Sharma MR; Koltowski L; Ownbey RT; Tuszynski GP; Sharma MC
Exp Mol Pathol; 2006 Oct; 81(2):146-56. PubMed ID: 16643892
[TBL] [Abstract][Full Text] [Related]
10. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
Kim S; Lee J; Jeon M; Lee JE; Nam SJ
Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
[TBL] [Abstract][Full Text] [Related]
11. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.
Wang X; Osada T; Wang Y; Yu L; Sakakura K; Katayama A; McCarthy JB; Brufsky A; Chivukula M; Khoury T; Hsu DS; Barry WT; Lyerly HK; Clay TM; Ferrone S
J Natl Cancer Inst; 2010 Oct; 102(19):1496-512. PubMed ID: 20852124
[TBL] [Abstract][Full Text] [Related]
12. Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model.
Kim E; Tunset HM; Cebulla J; Vettukattil R; Helgesen H; Feuerherm AJ; Engebråten O; Mælandsmo GM; Johansen B; Moestue SA
BMC Cancer; 2016 Mar; 16():191. PubMed ID: 26951085
[TBL] [Abstract][Full Text] [Related]
13. Targeted Nanocurcumin Therapy Using Annexin A2 Anitbody Improves Tumor Accumulation and Therapeutic Efficacy Against Highly Metastatic Breast Cancer.
Mukerjee A; Ranjan AP; Vishwanatha JK
J Biomed Nanotechnol; 2016 Jul; 12(7):1374-92. PubMed ID: 29336533
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of triple-negative and Herceptin-resistant breast cancer cell proliferation and migration by Annexin A2 antibodies.
Chaudhary P; Thamake SI; Shetty P; Vishwanatha JK
Br J Cancer; 2014 Dec; 111(12):2328-41. PubMed ID: 25321192
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effect of emodin on migration, invasion and metastasis of human breast cancer MDA-MB-231 cells in vitro and in vivo.
Sun Y; Wang X; Zhou Q; Lu Y; Zhang H; Chen Q; Zhao M; Su S
Oncol Rep; 2015 Jan; 33(1):338-46. PubMed ID: 25370743
[TBL] [Abstract][Full Text] [Related]
16. Arsenic sulfide inhibits cell migration and invasion of gastric cancer in vitro and in vivo.
Zhang L; Kim S; Ding W; Tong Y; Zhang X; Pan M; Chen S
Drug Des Devel Ther; 2015; 9():5579-90. PubMed ID: 26487802
[TBL] [Abstract][Full Text] [Related]
17. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.
Mehta PP; Whalen P; Baxi SM; Kung PP; Yamazaki S; Yin MJ
Clin Cancer Res; 2011 Aug; 17(16):5432-42. PubMed ID: 21715568
[TBL] [Abstract][Full Text] [Related]
18. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
[TBL] [Abstract][Full Text] [Related]
19. Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells.
Qiu M; Peng Q; Jiang I; Carroll C; Han G; Rymer I; Lippincott J; Zachwieja J; Gajiwala K; Kraynov E; Thibault S; Stone D; Gao Y; Sofia S; Gallo J; Li G; Yang J; Li K; Wei P
Cancer Lett; 2013 Jan; 328(2):261-70. PubMed ID: 23041621
[TBL] [Abstract][Full Text] [Related]
20. Annexin A2 and its downstream IL-6 and HB-EGF as secretory biomarkers in the differential diagnosis of Her-2 negative breast cancer.
Shetty P; Patil VS; Mohan R; D'souza LC; Bargale A; Patil BR; Dinesh US; Haridas V; Kulkarni SP
Ann Clin Biochem; 2017 Jul; 54(4):463-471. PubMed ID: 27496793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
